Comparison · NCT00250458-sae
Rizatriptan 10 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rizatriptan 10 mg vs Placebo: serious adverse events. Trial comparisons, record NCT00250458-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00250458-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0.00000000000000000173 | 0.0188 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0381 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0381 | 0.0188 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rizatriptan 10 mg | Rizatriptan 10 mg Orally Disintegrating Tablet (ODT), one dose, to treat a single migraine attack | 0 | 200 | EG000 |
| Group 2 | Placebo | Placebo matching Rizatiptan 10 mg ODT, one dose, to treat a single migraine attack | 0 | 97 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Reporting of adverse experiences from the time of informed consent to Visit 2. All serious adverse experiences that occur during this period and up to 14 days postdose of study therapy.
Source ClinicalTrials.gov
Trial
- Title
- Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea
- NCT number
- NCT00250458
- Phases
- PHASE3
- Conditions
- Migraine
- Interventions
- Comparator: Rizatriptan, Comparator: Placebo
- Lead sponsor
- Organon and Co
- Results first posted
- 2010-06-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00250458?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00250458-sae